Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease.

Literature DB >> 33239526

Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease.

Timothy Lawn¹, Yahyah Aman², Katarina Rukavina^3,4, George Sideris-Lampretsas⁵, Matthew Howard¹, Clive Ballard⁶, Kallol Ray Chaudhuri^3,4, Marzia Malcangio⁵.

Abstract

Entities: Chemical

Mesh：

Year: 2021 PMID： 33239526 PMCID： PMC7977618 DOI： 10.1097/j.pain.0000000000002111

Source DB: PubMed Journal: Pain ISSN： 0304-3959 Impact factor: 7.926

× No keyword cloud information.

153 in total

1. Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients.

Authors: A M Mathieu-Kia; L Q Fan; M J Kreek; E J Simon; J M Hiller
Journal: Brain Res Date: 2001-03-02 Impact factor: 3.252

Review 2. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?

Authors: E Braak; K Griffing; K Arai; J Bohl; H Bratzke; H Braak
Journal: Eur Arch Psychiatry Clin Neurosci Date: 1999 Impact factor: 5.270

3. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors: R Spanagel; A Herz; T S Shippenberg
Journal: Proc Natl Acad Sci U S A Date: 1992-03-15 Impact factor: 11.205

Review 4. A comprehensive review of the placebo effect: recent advances and current thought.

Authors: Donald D Price; Damien G Finniss; Fabrizio Benedetti
Journal: Annu Rev Psychol Date: 2008 Impact factor: 24.137

5. Non-motor features of Parkinson disease.

Authors: Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal: Nat Rev Neurosci Date: 2017-07-13 Impact factor: 34.870

6. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study.

Authors: Dyveke T Demant; Karen Lund; Jan Vollert; Christoph Maier; Märtha Segerdahl; Nanna B Finnerup; Troels S Jensen; Søren H Sindrup
Journal: Pain Date: 2014-08-17 Impact factor: 6.961

Review 7. Pain in Parkinson's disease: new concepts in pathogenesis and treatment.

Authors: Katarina Rukavina; Valentina Leta; Carolina Sportelli; Yazead Buhidma; Susan Duty; Marzia Malcangio; Kallol Ray Chaudhuri
Journal: Curr Opin Neurol Date: 2019-08 Impact factor: 5.710

8. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.

Authors: Claudia Trenkwalder; K Ray Chaudhuri; Pablo Martinez-Martin; Olivier Rascol; Reinhard Ehret; Martin Vališ; Maria Sátori; Anna Krygowska-Wajs; Maria J Marti; Karen Reimer; Alexander Oksche; Mark Lomax; Julia DeCesare; Michael Hopp
Journal: Lancet Neurol Date: 2015-10-19 Impact factor: 44.182

9. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study.

Authors: Giovanni Defazio; Alfredo Berardelli; Giovanni Fabbrini; Davide Martino; Emiliana Fincati; Antonio Fiaschi; Giuseppe Moretto; Giovanni Abbruzzese; Roberta Marchese; Ubaldo Bonuccelli; Paolo Del Dotto; Paolo Barone; Elisa De Vivo; Alberto Albanese; Angelo Antonini; Margherita Canesi; Leonardo Lopiano; Maurizio Zibetti; Giuseppe Nappi; Emilia Martignoni; Paolo Lamberti; Michele Tinazzi
Journal: Arch Neurol Date: 2008-09

10. Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM).

Authors: Ane Erdal; Elisabeth Flo; Dag Aarsland; Clive Ballard; Dagrun D Slettebo; Bettina S Husebo
Journal: Drugs Aging Date: 2018-06 Impact factor: 3.923

3 in total